Method of Administering a Therapeutic
The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a hormonal treatment such as a combined estrogen/progestin therapeutic which specifically includes an oral contraceptive that at least partially prevents or compensates for an endometriosis related symptom.
1 . A method of administering a therapeutic, said method comprising the following steps:
assessing a predisposition for endometriosis in a subject that does not exhibit an endometriosis symptom, and
administering a therapeutic to said subject.
2 . The method of claim 1 , wherein said step of assessing is preceded by the step of detecting in the genetic material of said subject the presence of at least one genetic marker correlated with at least one endometriosis related condition.
3 . The method of claim 1 , wherein said therapeutic prevents or at least partially compensates for at least one endometriosis related condition.
4 . The method of claim 1 , wherein said therapeutic defines a substance that is at least partially comprised of at least one of estrogen, progesterone, progestin, testosterone, and a GnRH agonist.
5 . The method of claim 4 , wherein said progesterone further defines at least one progesterone of Desogestrel, Drospirenone, Ethynodiol, Levonorgestrel, Norethindrone, Norgestimate, and Norgestrel, and wherein said estrogen defines at least one estrogen of Mestranol, Estradiol, and Ethinyl, and wherein said testosterone defines Danazol.
6 . The method of claim 4 , wherein said GnRH agonist is combined with an add-back therapy to prevent a GnRH agonist side effect.
7 . The method of claim 6 , wherein said add-back therapy defines a dosage of at least one of estrogen, progestin, and tibolone, and wherein said dosage of at least one of estrogen, progestin, and tibolone is in an amount such that the effectiveness of said GnRH agonist is not substantially reduced.
8 . The method of claim 1 , wherein said therapeutic defines an oral contraceptive.
9 . The method of claim 1 , wherein said therapeutic defines an ovulation suppression substance.
10 . The method of claim 1 , wherein said therapeutic defines a hormonal treatment.
11 . The method of claim 1 , wherein said subject defines a human female subject.
12 . The method of claim 1 , wherein said step of assessing is preceded by the step of detecting in the genetic material of said subject the presence of at least one genetic marker correlated with at least one endometriosis related condition, and wherein said therapeutic prevents or at least partially compensates for at least one endometriosis related condition.
13 . The method of claim 12 , wherein said therapeutic defines a substance that is at least partially comprised of at least one of estrogen, progesterone, progestin, testosterone, and a GnRH agonist.
14 . The method of claim 13 , wherein said progesterone further defines at least one progesterone of Desogestrel, Drospirenone, Ethynodiol, Levonorgestrel, Norethindrone, Norgestimate, and Norgestrel, and wherein said estrogen defines at least one estrogen of Mestranol, Estradiol, and Ethinyl, and wherein said testosterone defines Danazol.
15 . The method of claim 13 , wherein said GnRH agonist is combined with an add-back therapy to prevent a GnRH agonist side effect.
16 . The method of claim 15 , wherein said add-back therapy defines a dosage of at least one of estrogen, progestin, and tibolone, and wherein said dosage of at least one of estrogen, progestin, and tibolone is in an amount such that the effectiveness of said GnRH agonist is not substantially reduced.
17 . The method of claim 12 , wherein said therapeutic defines an oral contraceptive.
18 . The method of claim 12 , wherein said therapeutic defines an ovulation suppression substance.
19 . The method of claim 12 , wherein said therapeutic defines a hormonal treatment.
20 . The method of claim 12 , wherein said subject defines a human female subject.
21 . A method of administering an oral contraceptive, said method comprising the following steps:
assessing a predisposition for endometriosis in a subject that does not exhibit an endometriosis symptom, and
administering an oral contraceptive to said subject.
22 . The method of claim 21 , wherein said step of assessing is preceded by the step of detecting in the genetic material of said subject the presence of at least one genetic marker correlated with at least one endometriosis related condition.
23 . The method of claim 21 , wherein said oral contraceptive prevents or at least partially compensates for at least one endometriosis related condition.
24 . The method of claim 21 , wherein said oral contraceptive defines a substance that is at least partially comprised of at least one of estrogen and progesterone.
25 . The method of claim 24 , wherein said progesterone further defines at least one progesterone of Desogestrel, Drospirenone, Ethynodiol, Levonorgestrel, Norethindrone, Norgestimate, and Norgestrel, and wherein said estrogen defines at least one estrogen of Mestranol, Estradiol, and Ethinyl.
26 . The method of claim 21 , wherein said oral contraceptive defines an ovulation suppression substance.
27 . The method of claim 21 , wherein said oral contraceptive defines a hormonal treatment.
28 . The method of claim 21 , wherein said subject defines a human female subject.
29 . The method of claim 21 , wherein said step of assessing is preceded by the step of detecting in the genetic material of said subject the presence of at least one genetic marker correlated with at least one endometriosis related condition, and wherein said oral contraceptive prevents or at least partially compensates for at least one endometriosis related condition.
30 . The method of claim 29 , wherein said oral contraceptive defines a substance that is at least partially comprised of at least one of estrogen and progesterone.
31 . The method of claim 30 , wherein said progesterone further defines at least one progesterone of Desogestrel, Drospirenone, Ethynodiol, Levonorgestrel, Norethindrone, Norgestimate, and Norgestrel, and wherein said estrogen defines at least one estrogen of Mestranol, Estradiol, and Ethinyl.
32 . The method of claim 29 , wherein said oral contraceptive defines an ovulation suppression substance.
33 . The method of claim 29 , wherein said oral contraceptive defines a hormonal treatment.
34 . The method of claim 29 , wherein said subject defines a human female subject.
35 . A method of administering an ovulation suppression substance, said method comprising the following steps:
assessing a predisposition for endometriosis in a subject that does not exhibit an endometriosis symptom, and
administering an ovulation suppression substance to said subject.
36 . The method of claim 35 , wherein said step of assessing is preceded by the step of detecting in the genetic material of said subject the presence of at least one genetic marker correlated with at least one endometriosis related condition.
37 . The method of claim 35 , wherein said ovulation suppression substance prevents or at least partially compensates for at least one endometriosis related condition.
38 . The method of claim 35 , wherein said ovulation suppression substance defines a substance that is at least partially comprised of at least one of estrogen and progesterone.
39 . The method of claim 38 , wherein said progesterone further defines at least one progesterone of Desogestrel, Drospirenone, Ethynodiol, Levonorgestrel, Norethindrone, Norgestimate, and Norgestrel, and wherein said estrogen defines at least one estrogen of Mestranol, Estradiol, and Ethinyl.
40 . The method of claim 35 , wherein said ovulation suppression substance defines an oral contraceptive.
41 . The method of claim 35 , wherein said ovulation suppression substance defines a hormonal treatment.
42 . The method of claim 35 , wherein said subject defines a human female subject.
43 . The method of claim 35 , wherein said step of assessing is preceded by the step of detecting in the genetic material of said subject the presence of at least one genetic marker correlated with at least one endometriosis related condition, and wherein said ovulation suppression substance prevents or at least partially compensates for at least one endometriosis related condition.
44 . The method of claim 43 , wherein said ovulation suppression substance defines a substance that is at least partially comprised of at least one of estrogen and progesterone.
45 . The method of claim 44 , wherein said progesterone further defines at least one progesterone of Desogestrel, Drospirenone, Ethynodiol, Levonorgestrel, Norethindrone, Norgestimate, and Norgestrel, and wherein said estrogen defines at least one estrogen of Mestranol, Estradiol, and Ethinyl.
46 . The method of claim 43 , wherein said ovulation suppression substance defines an oral contraceptive.
47 . The method of claim 43 , wherein said ovulation suppression substance defines a hormonal treatment.
48 . The method of claim 43 , wherein said subject defines a human female subject.
49 . A method of administering a therapeutic, said method comprising the following steps:
detecting in the genetic material of said subject the presence of at least one genetic marker correlated with at least one endometriosis related condition,
assessing a predisposition for endometriosis for said subject, and
administering a therapeutic to said subject.
50 . The method of claim 49 , wherein said therapeutic prevents or at least partially compensates for at least one endometriosis related condition.
51 . The method of claim 49 , wherein said therapeutic defines a substance that is at least partially comprised of at least one of estrogen, progesterone, progestin, testosterone, and a GnRH agonist.
52 . The method of claim 51 , wherein said progesterone further defines at least one progesterone of Desogestrel, Drospirenone, Ethynodiol, Levonorgestrel, Norethindrone, Norgestimate, and Norgestrel, and wherein said estrogen defines at least one estrogen of Mestranol, Estradiol, and Ethinyl, and wherein said testosterone defines Danazol.
53 . The method of claim 51 , wherein said GnRH agonist is combined with an add-back therapy to prevent a GnRH agonist side effect.
54 . The method of claim 53 , wherein said add-back therapy defines a dosage of at least one of estrogen, progestin, and tibolone, and wherein said dosage of at least one of estrogen, progestin, and tibolone is in an amount such that the effectiveness of said GnRH agonist is not substantially reduced.
55 . The method of claim 49 , wherein said therapeutic defines an oral contraceptive.
56 . The method of claim 49 , wherein said therapeutic defines an ovulation suppression substance.
57 . The method of claim 49 , wherein said therapeutic defines a hormonal treatment.
58 . The method of claim 49 , wherein said subject defines a human female subject.
59 . The method of claim 49 , wherein said subject does not exhibit an endometriosis symptom.
60 . The method of claim 59 , wherein said therapeutic prevents or at least partially compensates for at least one endometriosis related condition.
61 . The method of claim 59 , wherein said therapeutic defines a substance that is at least partially comprised of at least one of estrogen, progesterone, testosterone, and a GnRH agonist.
62 . The method of claim 61 , wherein said progesterone further defines at least one progesterone of Desogestrel, Drospirenone, Ethynodiol, Levonorgestrel, Norethindrone, Norgestimate, and Norgestrel, and wherein said estrogen defines at least one estrogen of Mestranol, Estradiol, and Ethinyl, and wherein said testosterone defines Danazol.
63 . The method of claim 61 , wherein said GnRH agonist is combined with an add-back therapy to prevent a GnRH agonist side effect.
64 . The method of claim 63 , wherein said add-back therapy defines a dosage of at least one of estrogen, progestin, and tibolone, and wherein said dosage of at least one of estrogen, progestin, and tibolone is in an amount such that the effectiveness of said GnRH agonist is not substantially reduced.
65 . The method of claim 59 , wherein said therapeutic defines an oral contraceptive.
66 . The method of claim 59 , wherein said therapeutic defines an ovulation suppression substance.
67 . The method of claim 59 , wherein said therapeutic defines a hormonal treatment.
68 . The method of claim 59 , wherein said subject defines a human female subject.